its now may steady buying today patent in usa or trial news from canada will send this soaring imho

going blue l2 2v1

ready for another move up l2 3v1

now 4v1 ,company account are out and they wont need money for another year minimum

online limits dropped to 100,000 from 500,000 l2 2v1

online limits buy 100,000@1.1 v sell 500,000@1.06.l2 2v1 looking very strong update on zolpidem clinical trials overdue

anyone heard anything recently on this share..there seems to be a steady flow of buys growning..i have gathered some along the way

watcher

New distribution deal in Poland today.

ReGen Therapeutics Plc has inked a deal with Tagerr Polska for the exclusive distribution and marketing of its nutritional supplement Colostrinin in Poland, it announced Tuesday (June 2).

"Poland is the country where Colostrinin was first discovered and we know from various communications that there is significant knowledge of the product in Poland," said ReGen chairman and CEO Percy Lomax. "Both Tagerr and ourselves are optimistic that the volume of sales here should be significant."

Colostrinin is marketed as a nutritional supplement to support healthy brain ageing and cognition in humans and is currently available in the US, Canada and Australia under the brand name CogniSure, and in Cyprus as Cognase.

Tagerr Polska is an affiliate of German professional services and trading company Tagerr.


Story provided by Business Financial Newswire

Barclays are building a stake. News a couple of days ago about a marketing deal in the UK. It's been a long wait but just may, I say may, be about to move. Check it out.

She's building support, maybe about to move and maybe worth a look. I hold 40,000 so I am trying to talk it up but it ticked up a few days ago and then fell back but just ticked up again. Maybe worth a smallish punt. DYOR. But history shows that you do have to be careful with this one, having said that I really have no idea where it's going but it's beginning to look better. Any comments would be helpful. By the way I can lose the lot on this because I reinvested what I gained back in 2002, hope it goes up though.

Up 41% in a week, Barclay's now hold 14.21%.

http://news.bbc.co.uk/2/hi/health/8237686.stm

Two potentially key genes linked to the development of Alzheimer's disease have been uncovered by UK researchers.

It is the first gene clue to the condition in 16 years and has prompted scientists to rethink their theories on how the disease develops.

The genes were pinpointed in a study of 16,000 DNA samples and are known to be implicated in inflammation and cholesterol breakdown.

It is hoped the Nature Genetics study will open the way for new treatments.

The last and only gene to be linked to the common form of Alzheimer's disease is APOE4 gene, which has been the focus of much research.


These discoveries will enable scientists to follow new avenues of investigation as they piece together the causes of Alzheimer's disease - likely to be a mixture of genes, life style and life events
Dr Susanne Sorensen, Alzheimer's Society

Data from the latest work, a team effort of several UK universities, was shared with French researchers who identified a third gene, CR1, also reported in the journal.

The two genes uncovered by the UK team - CLU and PICALM - are both known to have protective roles in the brain.

Changes in the genes may either remove that protective effect or turn the "protectors into attackers", the researchers said.

One of the team, Professor Kevin Morgan from the University of Nottingham, explained that the pathways highlighted by the discovery include those involved in the turnover of cholesterol and part of the immune system involved in inflammation.

"These new pathways highlight potential new avenues for treatment using conventional drugs.

"The question now is if we lower cholesterol and reduce inflammation, could we modify the risk of people getting Alzheimer's disease."

'Valuable leads'

There are 700,000 people living with dementia in the UK, a number predicted to reach 1.7 million by 2050.

Study leader Professor Julie Williams, who is also chief scientific adviser to the Alzheimer's Research Trust, said the research would provide "valuable leads".

"We have been looking at a specific theory about Alzheimer's disease but our data shows that there are different things going on.

"We do not really understand what causes common Alzheimer's disease.

"In a few years' time we might have a very good idea of the full picture."

The study was carried out by teams in Cardiff, London, Cambridge, Nottingham, Southampton, Manchester, Oxford, Bristol and Belfast and further research involving 60,000 people is being planned for the next year.

Rebecca Wood, chief executive of the Alzheimer's Research Trust, said: "At a time when we are yet to find ways of halting this devastating condition, this development is likely to spark off numerous new ideas, collaborations and more in the race for a cure."

Dr Susanne Sorensen from the Alzheimer's Society said the work was exciting.

"These discoveries will enable scientists to follow new avenues of investigation as they piece together the causes of Alzheimer's disease - likely to be a mixture of genes, lifestyle and life events."

Watcher, are you still "watching" these or even hold, see it's on the rise but no more recent news about it gene work. Any info?? BB

been keeping an eye on these for progress on distribution into europe and other markets.....hasn't helped that they seem to be dipping on cash flow.....so the progress has been slow....happy to be in and hold....but patients needed....see how they are in the autumn....slow to meet potential.....but cant see them going down much further.....neck out time......have a good weekend BB

lots of trades in the last 3 days

things are improving all the time for little RGT.....picking up contracts.....trials progressing and the s.p. will of course reflect this......see where we are Q2 2011